Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Oncogene

• Publication date

  2000-02-03

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/sj.onc.1203354PMID 10698507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flt3 signaling involves tyrosyl‐phosphorylation of SHP‐2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells

  1999cited by this paper
• Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine‐dependent growth of hematopoietic cells

  1999cited by this paper
• IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line

  1999cited by this paper
• Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction.

  1999cited by this paper
• FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates

  1998cited by this paper
• Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway.

  1998cited by this paper
• Differential constitutive activation between STAT‐related proteins and MAP kinase in primary acute myelogenous leukaemia

  1998influential reference
• The CBL-related Protein CBLB Participates in FLT3 and Interleukin-7 Receptor Signal Transduction in Pro-B Cells*

  1998cited by this paper
• Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

  1998influential reference
• Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF β-receptor juxtamembrane and kinase insert domains

  1998cited by this paper
• Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

  1997cited by this paper
• Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

  1997cited by this paper
• Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells

  1997cited by this paper
• Effects of flt3 ligand on acute myeloid and lymphocytic leukemic blast cells from children.

  1996cited by this paper
• The role of MAP kinase kinase in interleukin-3 stimulation of proliferation.

  1996cited by this paper
• Suppression of interleukin‐3‐induced gene expression by a C‐terminal truncated Stat5: role of Stat5 in proliferation.

  1996cited by this paper
• Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax.

  1996cited by this paper
• Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins

  1996cited by this paper
• Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.

  1996cited by this paper
• Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

  1995cited by this paper
• Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

  1995cited by this paper
• Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors.

  1995cited by this paper
• Inhibition of MAP Kinase Kinase Blocks the Differentiation of PC-12 Cells Induced by Nerve Growth Factor(*)

  1995cited by this paper
• Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response.

  1994cited by this paper
• Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells

  1993cited by this paper
• Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.

  1993cited by this paper
• Receptor tyrosine kinases

  1992cited by this paper
• Interleukin-3 regulates the activity of the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines.

  1992cited by this paper
• A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations.

  1991cited by this paper
• Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family.

  1991cited by this paper
• Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene.

  1991cited by this paper
• Growth factor receptor tyrosine kinases.

  1988cited by this paper

• Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics.

  2025cites this paper
• Downregulation of S6 Kinase and Hedgehog–Gli1 by Inhibition of Fatty Acid Synthase in AML with FLT3-ITD Mutation

  2025cites this paper
• Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib: a case report

  2025cites this paper
• Genomic profiles of myelodysplastic neoplasm with bone marrow eosinophilia or basophilia: Inflammatory drivers and DNA damage response.

  2025cites this paper
• Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia

  2025cites this paper
• Oncogenic FLT3 internal tandem duplications (ITD) and CD45/PTPRC control osteoclast functions and bone microarchitecture

  2025cites this paper
• Current and future of targeted therapies against BCR::ABL kinases

  2025cites this paper
• Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy

  2025cites this paper
• Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation

  2025cites this paper
• Homoharringtonine: mechanisms, clinical applications and research progress

  2025cites this paper
• Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.

  2024cites this paper
• Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors.

  2024cites this paper
• Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy.

  2024cites this paper
• Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

  2024cites this paper
• Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential

  2024cites this paper
• FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia

  2024cites this paper
• Advancements and Challenges in the Treatment of AML.

  2024cites this paper
• Mechanisms of Resistance to Targeted Therapies in AML

  2024cites this paper
• Constitutive Flt3 signaling impacts conventional dendritic cell function

  2024cites this paper
• Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling

  2024cites this paper
• Modelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients

  2024cites this paper
• C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia.

  2023cites this paper
• The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate

  2023cites this paper
• Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.

  2023cites this paper
• Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon

  2023cites this paper
• How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia

  2023cites this paper
• A critical role for PLCG1 in RAS activation by BCR-ABL1 and FLT3-ITD

  2023cites this paper
• A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development

  2023cites this paper
• Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia

  2023cites this paper
• Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release

  2023cites this paper
• C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemia

  2022cites this paper
• FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta‐analysis

  2022cites this paper
• Resistance to targeted therapies in acute myeloid leukemia

  2022cites this paper
• Disrupting PTPRJ transmembrane-mediated oligomerization counteracts oncogenic receptor tyrosine kinase FLT3 ITD

  2022cites this paper
• Panel Analysis: Hematological Malignancies

  2022cites this paper
• PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia

  2022cites this paper
• Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations

  2022cites this paper
• “FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors

  2022cites this paper
• Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS‐like tyrosine kinase 3‐internal tandem duplication with central nervous system involvement

  2022cites this paper
• FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation

  2022cites this paper
• FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs

  2022cites this paper
• Resistance to targeted therapies: delving into FLT3 and IDH

  2022cites this paper
• FLT3-targeted treatment for acute myeloid leukemia

  2022cites this paper
• Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies

  2022cites this paper
• Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia

  2022cites this paper
• The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia

  2022influential citation
• A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib

  2022cites this paper
• Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors

  2022cites this paper
• Acute promyelocytic leukemia with myelofibrosis

  2021cites this paper
• Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.

  2021cites this paper
• OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia

  2021cites this paper
• The importance of Ras in drug resistance in cancer

  2021cites this paper
• Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective

  2021cites this paper
• Inhibitory effects of Tomivosertib in acute myeloid leukemia

  2021cites this paper
• The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML

  2021cites this paper
• FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia

  2021cites this paper
• GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD–Mutant Acute Myeloid Leukemia

  2021cites this paper
• A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.

  2021cites this paper
• Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

  2021cites this paper
• FLT3 Gene Mutation in Acute Myeloid Leukemia: Correlation with Hematological, Immunophenotypic, and Cytogenetic Characteristics

  2021cites this paper
• Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.

  2021cites this paper
• Targeted therapy of human leukemia xenografts in immunodeficient zebrafish

  2021cites this paper
• LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

  2021cites this paper
• A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors

  2021cites this paper
• Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1.

  2021cites this paper
• Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia

  2021cites this paper
• Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

  2020cites this paper
• Implications and Limitations

  2020cites this paper
• Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition

  2020cites this paper
• Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

  2020cites this paper
• The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis

  2020cites this paper
• FLT3-ITD及CEBPA基因共突变成人急性髓系白血病患者的临床特征及预后分析

  2020cites this paper
• Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies

  2020cites this paper
• Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia

  2020cites this paper
• Quizartinib for the treatment of acute myeloid leukemia

  2020cites this paper
• FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.

  2020cites this paper
• Comparing the area under the curve and peak height methods in the calculation of FLT3‐ITD allelic ratio

  2020cites this paper
• Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

  2020cites this paper
• Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

  2020cites this paper
• FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.

  2020cites this paper
• Mouse Models of Myeloid Malignancies.

  2020cites this paper
• Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

  2020cites this paper
• Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2020cites this paper
• Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system

  2020cites this paper
• FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

  2020cites this paper
• The Evolving AML Genomic Landscape: Therapeutic Implications.

  2020cites this paper
• [Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways].

  2020cites this paper
• Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration.

  2020cites this paper
• FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development

  2019cites this paper
• Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells

  2019cites this paper
• PROTACs: great opportunities for academia and industry

  2019cites this paper
• Discovery of LDD-1075 as a potent FLT3 inhibitor.

  2019cites this paper
• Exploring the role of the Notch signallingpathway in normal and malignant humanhaematopoiesis

  2019cites this paper
• Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia

  2019cites this paper
• Modeling the Hematopoietic Landscape

  2019cites this paper
• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

  2019cites this paper
• Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

  2019cites this paper
• Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia

  2019cites this paper
• Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

  2019cites this paper
• Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation

  2019cites this paper